HOMEPAGE / INDUSTRY / CHEMICAL INDUSTRY

BAYER – Group report and key figures

REPORT’S MAIN STRENGTHS :

A report presented through summary slides of group's operations
Detailed history of financial performances between 2020 and 2024
An overview of the group's major business strategies
A medium-term outlook for opportunities and threats

ADD TO BASKET | 650 €ADD TO BASKET | 650 €

Collection : Essential

Last update : 30/06/2025

Price : 650 €

Number of pages : 23 pages

Language : English

Format : PDF (immediate availability)

Reference : 25XENT20

DOWNLOAD THE PRESENTATION

IN THIS REPORT

SUMMARY

RELATED REPORTS

DOWNLOAD
THE PRESENTATION

IN THIS REPORT

WHAT IS THE GROUPS' FINANCIAL SITUATION ?

The financial indicators presented in this report include: consolidated revenue, consolidated EBIT and EBIT ratio, consolidated net profit and net profit rate, R&D expenditure and ratio, sales by segment and by region, profitability, liquidity and solvency ratios, free cash flow and capital expenditure.

WHAT ARE THE GROUP'S STRATEGIC PRIORITIES ?

Accelerate pharmaceutical pipeline transition

Mitigate legal risks while transitioning Crop Science portfolio

Restructure operations via Dynamic Shared Ownership

WHAT ARE THE GROUP'S STRENGTHS AND WEAKNESSES ?

Through a SWOT analysis, this report also provides an overview of the group's strengths (deep production capabilities and customer networks, etc.) and weaknesses (persistent legal overhang related to glyphosate litigation, with €5.7bn in provisions as of 2024, etc.).

SUMMARY